Literature DB >> 2145893

Absence of abnormalities of the c-erbB-1 and c-erbB-2 proto-oncogenes in human thyroid neoplasia.

N R Lemoine1, F S Wyllie, J R Lillehaug, S L Staddon, C M Hughes, R Aasland, J Shaw, J E Varhaug, C L Brown, W J Gullick.   

Abstract

The c-erbB-1 and c-erbB-2 proto-oncogenes are frequently activated by gene amplification and overexpression in a variety of human cancers. In an analysis of a large series of benign and malignant thyroid tumours, no abnormalities of structure or expression of either of c-erbB-1 or c-erbB-2 were found. Activation of these oncogenes is not a necessary event in neoplasia of this epithelial system.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2145893     DOI： 10.1016/0277-5379(90)90149-n

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  10 in total

1.  Lack of HER-2 gene amplification and association with pathological and clinical characteristics of differentiated thyroid cancer.

Authors:  Wahid Mdah; Raneen Mzalbat; Peter Gilbey; Moshe Stein; Adi Sharabi; Jamal Zidan
Journal:  Mol Clin Oncol       Date:  2014-07-11

2.  Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease.

Authors:  R Kremser; P Obrist; G Spizzo; H Erler; D Kendler; G Kemmler; G Mikuz; C Ensinger
Journal:  Virchows Arch       Date:  2003-03-08       Impact factor: 4.064

3.  C-erbB-2 immunostaining: problems with interpretation.

Authors:  E W Kay; C J Walsh; M Cassidy; B Curran; M Leader
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

4.  Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein.

Authors:  W J Gullick; A C Bottomley; F J Lofts; D G Doak; D Mulvey; R Newman; M J Crumpton; M J Sternberg; I D Campbell
Journal:  EMBO J       Date:  1992-01       Impact factor: 11.598

5.  Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer.

Authors:  N R Lemoine; S Jain; F Silvestre; C Lopes; C M Hughes; E McLelland; W J Gullick; M I Filipe
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

6.  Expression of growth factor receptors in human brain tumours.

Authors:  N L Tuzi; D J Venter; S Kumar; S L Staddon; N R Lemoine; W J Gullick
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

7.  Expression of c-erbB-2 protein in papillary thyroid carcinomas.

Authors:  D R Haugen; L A Akslen; J E Varhaug; J R Lillehaug
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

8.  HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin.

Authors:  Rosaria M Ruggeri; Alfredo Campennì; Giuseppe Giuffrè; Luca Giovanella; Massimiliano Siracusa; Angela Simone; Giovanni Branca; Rosa Scarfì; Francesco Trimarchi; Antonio Ieni; Giovanni Tuccari
Journal:  Int J Mol Sci       Date:  2016-12-06       Impact factor: 5.923

9.  Prognostic impact of EGF-receptor in papillary thyroid carcinoma.

Authors:  L A Akslen; A O Myking; H Salvesen; J E Varhaug
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

10.  Multiple Functions of Fubp1 in Cell Cycle Progression and Cell Survival.

Authors:  Mingyu Kang; Hyeon Ji Kim; Tae-Jun Kim; Jin-Seok Byun; Jae-Ho Lee; Deok Heon Lee; Wanil Kim; Do-Yeon Kim
Journal:  Cells       Date:  2020-05-28       Impact factor: 6.600
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.